J&J’s Janssen touts Ph3 data for antidepressant nasal spray

Johnson & Johnson‘s (NYSE:JNJ) Janssen revealed data from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression.

The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 years.